As of the latest Form 4 filed May 26, 2026.
What Ginkgo Bioworks Holdings insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 35 most recent filings for DNA.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | 2026-05-22 | Coen Steven P. See remarks | SSale | −307.00 | $8.33 | $2.56K | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Coen Steven P., See remarks | MExercise | +156.00 | — | — | No | Form 4 ↗ |
| 2026-05-26 | 2026-05-21 | Coen Steven P., See remarks | MExercise | +587.00 | — | — | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-17 | Coen Steven P. See remarks | SSale | −324.00 | $7.95 | $2.58K | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-16 | Coen Steven P., See remarks | MExercise | +156.00 | — | — | No | Form 4 ↗ |
| 2026-04-20 | 2026-04-16 | Coen Steven P., See remarks | MExercise | +587.00 | — | — | No | Form 4 ↗ |
| 2026-04-14 | 2026-04-13 | Coen Steven P. See remarks | SSale | −33.2K | $6.41 | $213K | No | Form 4 ↗ |
| 2026-04-14 | 2026-04-10 | Coen Steven P., See remarks | MExercise | +45.6K | — | — | No | Form 4 ↗ |
| 2026-04-14 | 2026-04-10 | Coen Steven P., See remarks | MExercise | +28.4K | — | — | No | Form 4 ↗ |
| 2026-04-13 | 2026-04-10 | Canton Barry 10% owner | SSale | −125K | $6.43 | $802K | No | Form 4 ↗ |
| 2026-04-13 | 2026-04-10 | Shetty Reshma P. See remarks | SSale | −125K | $6.43 | $802K | No | Form 4 ↗ |
| 2026-04-13 | 2026-04-09 | Canton Barry 10% owner | MExercise | +252K | — | — | No | Form 4 ↗ |
| 2026-04-13 | 2026-04-09 | Shetty Reshma P. See remarks | MExercise | +252K | — | — | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-09 | Shetty Reshma P. See remarks | SSale | −13.1K | $6.40 | $83.9K | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-09 | Canton Barry 10% owner | SSale | −13.1K | $6.40 | $83.9K | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-09 | Kelly Jason R See remarks | SSale | −110K | $6.40 | $702K | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-08 | Shetty Reshma P. See remarks | SSale | −13.2K | $6.93 | $91.2K | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-08 | Shetty Reshma P., See remarks | MExercise | +27.7K | — | — | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-08 | Canton Barry 10% owner | SSale | −13.2K | $6.93 | $91.2K | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-08 | Canton Barry, 10% owner | MExercise | +27.7K | — | — | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-08 | Kelly Jason R See remarks | SSale | −97.0K | $6.93 | $672K | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-08 | Kelly Jason R, See remarks | MExercise | +213K | — | — | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-07 | Shetty Reshma P. See remarks | MExercise | +27.7K | — | — | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-07 | Canton Barry 10% owner | MExercise | +27.7K | — | — | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-07 | Kelly Jason R See remarks | MExercise | +213K | — | — | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-16 | Coen Steven P. See remarks | SSale | −708.00 | $6.74 | $4.77K | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-13 | Coen Steven P., See remarks | MExercise | +312.00 | — | — | No | Form 4 ↗ |
| 2026-03-18 | 2026-03-13 | Coen Steven P., See remarks | MExercise | +1.17K | — | — | No | Form 4 ↗ |
| 2026-01-22 | 2026-01-20 | Coen Steven P. See remarks | SSale | −972.00 | $8.92 | $8.67K | No | Form 4 ↗ |
| 2026-01-22 | 2026-01-16 | Coen Steven P., See remarks | MExercise | +1.06K | — | — | No | Form 4 ↗ |
| 2026-01-22 | 2026-01-16 | Coen Steven P., See remarks | MExercise | +156.00 | — | — | No | Form 4 ↗ |
| 2026-01-22 | 2026-01-16 | Coen Steven P., See remarks | MExercise | +587.00 | — | — | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-15 | Coen Steven P. See remarks | SSale | −736.00 | $8.89 | $6.54K | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-12 | Coen Steven P., See remarks | MExercise | +312.00 | — | — | No | Form 4 ↗ |
| 2025-12-16 | 2025-12-12 | Coen Steven P., See remarks | MExercise | +1.17K | — | — | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also DNA’s full analysis or the market-wide insider trading feed. The tabs above jump to DNA’s other SEC data.
Source: SEC Form 4 filings for DNA, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.